



1fw

PATENT
ATTORNEY DOCKET NO. 50150/057002

Certificate of Mailing: Date of Deposit: March 31, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon

Printed name of person mailing correspondence

Susan M Cannon
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Chalom B. Sayada	Art Unit:	1614
Serial No.:	10/735,344	Examiner:	Not yet assigned
Filed:	December 11, 2003	Customer No.:	21559
Title:	METHODS AND REAGENTS FOR TREATING OR PREVENTING ATHEROSCLEROSIS AND DISEASES ASSOCIATED THEREWITH		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. Applicant also wishes to make of record co-pending U.S. applications 10/443,351 and 10/651,865.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is

material to patentability.

This statement is being filed before the receipt of a first Office action on the merits. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.


Respectfully submitted,

Date: 3/31/05



Karen L. Elbing, Ph.D.

Reg. No. 35,238


Reg. No. 52,608

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50150/057002
		Serial No.	10/735,344
		Applicant	Chalom B. Sayada
		Filing Date	December 11, 2003
		Group	1614
		IDS Filed	March 31, 2005
		Customer No.	21559

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,690,919	09/01/87	Yamane et al.			
	4,859,661	08/22/89	Kano et al.			
	4,983,602	01/08/91	Yamane et al.			
	5,424,187	06/13/95	Shor et al.			
	5,786,349	07/28/98	Yamashita et al.			
	5,830,874	11/03/98	Shor et al.			
	5,935,926	08/10/99	Scarborough			
	5,981,522	11/09/99	Yamashita et al.			
	6,093,743	07/25/00	Lai et al.			
	6,043,225	03/28/00	Shor et al.			
	6,258,532	07/10/01	Stratton et al.			
	6,281,199	08/28/01	Gupta			
	6,316,433	08/28/01	Rose et al.			
	6,432,962	08/13/02	Horneman			
	6,475,518	11/05/01	Baumgart et al.			
	6,565,828	05/20/03	Liu			
	6,566,354	05/20/03	Rose et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50150/057002 Serial No. 10/735,344 Applicant Chalom B. Sayada Filing Date December 11, 2003 Group 1614 IDS Filed March 31, 2005 Customer No. 21559				
U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Issue or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,579,854	06/17/03	Mitchell et al.			
	6,664,239	12/16/03	Mitchell et al.			
	6,756,369	06/29/04	Mitchell et al.			
	2003-0045678	03/06/03	Keith et al.			
	2003-0203903	10/30/03	Rose et al.			
	2003-0236265	12/25/03	Sayada			
	2004-0077533	4/22/04	Sayada			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	EP 0 192033	08/27/86	Europe			
	EP 0 337733	10/18/89	Europe			
	WO 92/20352	11/26/92	WIPO			
	EP 0 546761	06/16/93	Europe			
	EP 0 699688	03/06/96	Europe			
	WO 98/50074	11/12/98	WIPO			
	WO 01/44272 A2	06/21/01	WIPO			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Anderson et al., "The ACADEMIC study in perspective (azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia)," <i>The Journal of Infectious Diseases</i> 181:S569-S571, (2000).					
	Anestad et al., "Chronic infections and coronary heart disease," <i>The Lancet</i> 350:1028, (1997).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed Customer No.	50150/057002 10/735,344 Chalom B. Sayada December 11, 2003 1614 March 31, 2005 21559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
Berkow et al., "Diabetes Mellitus," The Merck Manual Ed., Pocket Books, New York, pages 788-795, 2000.			
Boman et al., " <i>Chlamydia pneumoniae</i> and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies," <i>Clinical Microbiology Reviews</i> 15:1-20, (2002).			
Campbell et al., " <i>Chlamydia pneumoniae</i> and atherosclerosis," <i>Seminars in Respiratory Infections</i> 18:48-54, (2003).			
Dugan et al., "Review of evidence for a connection between <i>Chlamydia pneumoniae</i> and atherosclerotic disease," <i>Clinical Therapeutics</i> 24:719-735, (2002).			
Gabay et al., "Role of antibiotics for the prevention of cardiovascular Disease," <i>The Annals of Pharmacotherapy</i> 36:1629-1636, (2002).			
Gieffers et al., " <i>Chlamydia pneumoniae</i> infection In circulating human monocytes Is refractory to antibiotic treatment," <i>Circulation</i> 103:351-356, (2001).			
Grayston, "Antibiotic treatment of atherosclerotic cardiovascular disease," <i>Circulation</i> 107:1228-1230, (2003).			
Gupta et al., "Elevated <i>Chlamydia pneumoniae</i> antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction," <i>Circulation</i> 96:404-407, (1997).			
Gupta et al., " <i>Chlamydia pneumoniae</i> , antimicrobial therapy and coronary heart disease: a critical overview," <i>Coronary Artery Disease</i> 9:339-343, (1998).			
Gupta, "Chronic infection in the aetiology of atherosclerosis—focus on <i>Chlamydia pneumoniae</i> ," <i>Atherosclerosis</i> 143:1-6 (1999).			
Gurfinkel et al., " <i>Chlamydia pneumoniae</i> in coronary artery disease," <i>Circulation</i> 101:E118-119, (2002).			
Gurfinkel et al., "Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study," <i>The Lancet</i> 350:404-407, (1997).			
Halliwell et al., "Chronic infections and coronary heart disease," <i>The Lancet</i> 350:1030, (1997).			
Harvard University Gazette " <i>Chlamydia pneumoniae</i> may contribute to stroke, heart attacks," December 12, 2002.			
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50150/057002 Serial No. 10/735,344 Applicant Chalom B. Sayada Filing Date December 11, 2003 Group 1614 IDS Filed March 31, 2005 Customer No. 21559
	Higgins, " <i>Chlamydia pneumoniae</i> and coronary artery disease: the antibiotic trials," <i>Mayo Clinic Proceedings</i> 78:321-332, (2003).	
	Kuo et al., "A comparison of the in-vitro sensitivity of <i>Chlamydia pneumoniae</i> to macrolides and a new benzoxazinorifamycin, KRM-1648," <i>Infectious Disease and Therapy</i> , 21:317-321, 1997, Abstract.	
	Stone et al., "Effect of treatment for <i>Chlamydia pneumoniae</i> and <i>Helicobacter pylori</i> on markers of inflammation and cardiac events in patients with acute coronary syndromes, South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA)," <i>Circulation</i> 106:1219-1223 (2002).	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		